鲁索替尼治疗伴有PCM1-JAK2融合基因的B淋巴细胞白血病的疗效 - Suppr

Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.

作者信息

Wouters Yannick, Nevejan Louis, Louwagie Annelies, Devos Helena, Dewaele Barbara, Selleslag Dominik, Michaux Lucienne

机构信息

Department of Laboratory Medicine, Sint-Franciscus Hospital, Heusden-Zolder, Belgium.

Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.

出版信息

Br J Haematol. 2021 Feb;192(4):e112-e115. doi: 10.1111/bjh.17340. Epub 2021 Jan 27.

DOI:10.1111/bjh.17340

PMID:33502001

Abstract

摘要

相似文献

Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.

Br J Haematol. 2021 Feb;192(4):e112-e115. doi: 10.1111/bjh.17340. Epub 2021 Jan 27.

Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.

Blood Adv. 2019 Nov 26;3(22):3499-3502. doi: 10.1182/bloodadvances.2019000700.

Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.

Genes Chromosomes Cancer. 2022 Jan;61(1):55-58. doi: 10.1002/gcc.22995. Epub 2021 Sep 1.

The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and gene fusion presenting as B-lymphoblastic leukemia.

Cold Spring Harb Mol Case Stud. 2020 Apr 1;6(2). doi: 10.1101/mcs.a004937. Print 2020 Apr.

New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.

Haematologica. 2016 Apr;101(4):407-16. doi: 10.3324/haematol.2015.141101.

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23.

Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.

Br J Haematol. 2022 Feb;196(3):700-705. doi: 10.1111/bjh.17910. Epub 2021 Oct 25.

TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition.

Genes Chromosomes Cancer. 2024 Aug;63(8):e23261. doi: 10.1002/gcc.23261.

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.

Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26328. Epub 2016 Nov 15.

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.

Ann Hematol. 2015 Feb;94(2):233-8. doi: 10.1007/s00277-014-2221-y. Epub 2014 Sep 27.

引用本文的文献

The Use of Optical Genome Mapping for the Detection of Tyrosine Kinase Gene Fusions in Myeloid/Lymphoid Neoplasms.

J Cell Mol Med. 2025 Jun;29(12):e70640. doi: 10.1111/jcmm.70640.

NKD1 targeting PCM1 regulates the therapeutic effects of homoharringtonine on colorectal cancer.

Mol Biol Rep. 2023 Aug;50(8):6543-6556. doi: 10.1007/s11033-023-08572-5. Epub 2023 Jun 20.

PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.

Oncologist. 2022 Aug 5;27(8):e661-e670. doi: 10.1093/oncolo/oyac072.

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review.

Front Oncol. 2021 Oct 11;11:753842. doi: 10.3389/fonc.2021.753842. eCollection 2021.

The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia.

Cancers (Basel). 2021 Aug 30;13(17):4388. doi: 10.3390/cancers13174388.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.

作者信息

机构信息

出版信息

相似文献

引用本文的文献